



Article

One-Pot Synthesis of Benzoxazole/Benzothiazole-Substituted Esters by Michael Addition: A Selective Construction of C-N/C-S Bonds

Zhi-Ying Gong 1,†, Cheng-Li Yang 1,†, Dan Wang 1, Lang Huang 1 and Zhi-Bing Dong 1,2,3,*

- School of Chemistry and Environmental Engineering, Wuhan Institute of Technology, Wuhan 430205, China
- Key Laboratory of Green Chemical Process, Ministry of Education, Wuhan Institute of Technology, Wuhan 430205, China
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
- * Correspondence: dzb04982@wit.edu.cn
- † These authors contributed equally to this work.

Abstract: An efficient and convenient synthesis of benzoxazole/benzothiazole-substituted esters in a one-pot strategy is reported. In this investigation, a selective construction of C-N and C-S bonds via simple addition is performed. Thus, using substituted 2-aminophenols/2-aminobenzenethiols, TMTD (tetramethylthiuram disulfide) and α,β -unsaturated esters as starting substrates, C-N and C-S bonds can be selectively constructed by means of the Michael addition reaction. This protocol features high selectivity, high atomic economy, mild conditions, good functional tolerance and good to excellent yields, showing the potential value for the preparation of some biologically and pharmaceutically active compounds.

Keywords: benzoxazole; benzothiazole; synthesis; Michael addition; organosulfur



Citation: Gong, Z.-Y.; Yang, C.-L.; Wang, D.; Huang, L.; Dong, Z.-B. One-Pot Synthesis of Benzoxazole/Benzothiazole-Substituted Esters by Michael Addition: A Selective Construction of C-N/C-S Bonds. *Catalysts* **2023**, *13*, 658. https://doi.org/10.3390/ catal13040658

Academic Editors: Lianghua Zou and Xiaofeng Xia

Received: 25 February 2023 Revised: 20 March 2023 Accepted: 24 March 2023 Published: 27 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction


Compounds containing C-N/C-S bonds have become a key part in organic synthesis, biomedicine, material chemistry and industrial manufacturing [1–13]. Many heterocyclic compounds bearing C-N/C-S bonds are indispensable in pharmaceutical chemistry due to their unique biological and pharmaceutical activities (Figure 1). These compounds can be used as an anti-inflammatory (a) [14], a heat shock protein 90 (Hsp 90) an inhibitor (b) [15], a botanical fungicide or insecticide (c) [16], a CpIMPDH inhibitor (d) [17], a CCR₃ selective antagonist (e) [18], a lipoxygenase inhibitor (f) [19], an anticancer agent (g) [20] and an antinematode drug (h) [21]. Therefore, the construction of the C-N bond and the C-S bond has aroused the interest of the organic chemistry community.

So far, various methods for constructing C-N/S bonds have been reported (Scheme 1). Bolm [22], Buchwald [23], Chen [24] and Biswasa [25] realized the construction of the C-N bond by using aryl halides or alcohols to react with nitrogen-containing heterocyclic compounds. The most traditional method to form the C-S bond is the coupling reaction between thiols and aryl halides [26–31]. The Sokolova [32] and Ma [33] group completed the construction of the C-S bond under base conditions. In addition, Yuan and Hajra [34,35] used phenylhydrazine and phenylthiophenol as starting materials to obtain various compounds containing a C-S bond via visible-light-mediated synthesis or aerobic-oxidative coupling. Our laboratory and other groups [36–38] also completed the construction of the C-S bond through the Chan-Lam coupling reaction. To the best of our knowledge, the selective construction of C-N/C-S bonds has rarely been reported [39,40]. Though, efficient, the previously reported methods for the construction of C-N/C-S bonds involved the use of toxic, foul-smelling, and expensive reagents, transition metals as catalysts, a high reaction temperature, a long reaction time, as well as low conversion, which limited the application of these methods in pharmaceutical synthesis. Thus, it is still desirable to

Catalysts 2023, 13, 658 2 of 13

develop efficient protocols for the selective construction of C-N/C-S bonds, especially the ones using a tandem or one-pot synthesis strategy.

Figure 1. Representative biologically active compounds containing C-N/C-S bonds.



Scheme 1. Previous strategies for the synthesis of C-N/C-S bonds [22–38].

Catalysts 2023, 13, 658 3 of 13

As part of our long-term interest in constructing various C-X (X = O, S, N, P) bonds and studying the synthesis of benzoheterocyclic compounds [41–45], we report here an effective and practical method for the selective formation of C-N/C-S bonds by Michael addition reactions, starting from substituted 2-aminophenols/2-aminobenzenethiols and TMTD (tetramethylthiuram disulfide) with α,β -unsaturated esters in a one-pot strategy (Scheme 2, the present study).

This work

$$R^{1} \stackrel{\text{II}}{\text{II}} \longrightarrow SH$$
 $\parallel \text{(Dong, 2017)}$
 $R^{1} \stackrel{\text{II}}{\text{II}} \longrightarrow XH$
 $X = S, O$
 $R^{2} \longrightarrow R^{2}$
 $R^{1} \stackrel{\text{II}}{\text{II}} \longrightarrow XH$
 $R^{2} \longrightarrow R^{2}$
 $R^{2} \longrightarrow R^{2}$

Scheme 2. Selective formation of C-N/C-S bonds in one-pot strategy [45].

2. Results and Discussion

For our initial study, we chose 2-aminophenol (1a), tetramethylthiuram disulfide (TMTD) and ethyl acrylate (2a) as the starting materials for the model reaction to explore the optimal reaction conditions (Table 1). Our laboratory has previously made good progress in the synthesis of benzoheterocyclic compounds. The reaction conditions for the first step to produce 2-aminophenols were slightly adjusted based on our previous work [41-45], and our attempts were focused on the second step (the Michael addition reaction). Using CuI as the catalyst and Et₃N as the base in the initial attempt, the ideal product 3aa was obtained with a 19% yield of EtOH (Entry 1, Table 1). Next we tried other catalysts and found that the catalytic effect of CuI was slightly better (Entries 1–4, Table 1). We were surprised to find that the yield was greatly improved when DMF was used as the solvent (Entry 5, Table 1), and the result was better without adding metal salt as the catalyst (entry 6, Table 1). The screening of bases and reaction temperature showed that Et₃N was the best base and 80 °C was the optimal temperature (entries 7–12, Table 1). Furthermore, the loading of the base and the type of solvent were also investigated, and the results are shown in entries 13-16, Table 1. The optimal reaction conditions are summarized in Entry 10, Table 1. It is worth noting that the model reaction in Table 1 always produced the by-product 3aa' in traces which formed the C-S bond in the additional step.

According to the optimal conditions obtained above, a variety of related substrates are explored, and the results are presented in Table 2. First, the reaction effect of various substituted 2-aminophenols and ethyl acrylate was investigated, and the experimental results showed that 2-aminophenols with either electron-withdrawing groups (-Br, -Cl) or electron-donating groups (-CH₃, -^tBu) could react readily with ethyl acrylate to give the desired products with a moderate to good yield (3aa–3ah). When *tert*-butyl acrylate and cyclohexyl acrylate were used to react with various substituted 2-aminophenols, the reaction also worked well and provided the expected products (3ai–3av) readily. When 2-amino-3-methylphenol was used as the starting material to react with ethyl acrylate, *tert*-butyl acrylate and cyclohexyl acrylate, the compounds (3ah, 3aj, 3ar) could only be obtained in 28%, 29% and 36% yields, respectively, which might be due to the steric hindrance.

To further determine the structure of the target products, we performed an X-ray diffraction analysis of **3ai** (CCDC: 2152821, Figure 2) to show the exact C-N bond formation of the product.

Catalysts 2023, 13, 658 4 of 13

Table 1. Optimization of the reaction conditions ^a.

Entry	Cat.	Base	Temp. (°C)	Solvent	Yield ^b (%)
1	CuI	Et ₃ N (2.0 eq.)	60	EtOH	19
2	CuO	Et ₃ N (2.0 eq.)	60	EtOH	17
3	CuBr ₂	Et_3N (2.0 eq.)	60	EtOH	15
4	$FeCl_3$	Et ₃ N (2.0 eq.)	60	EtOH	<10
5	CuI	Et ₃ N (2.0 eq.)	60	DMF	48
6	-	Et ₃ N (2.0 eq.)	60	DMF	68
7	-	Na_2CO_3 (2.0 eq.)	60	DMF	53
8	-	$NaHCO_3$ (2.0 eq.)	60	DMF	52
9	-	$Et_2NH (2.0 eq.)$	60	DMF	60
10	-	Et_3N (2.0 eq.)	80	DMF	85
11	-	Et_3N (2.0 eq.)	100	DMF	84
12	-	Et_3N (2.0 eq.)	110	DMF	80
13	-	$Et_3N (1.0 eq.)$	80	DMF	70
14	-	Et ₃ N (3.0 eq.)	80	DMF	72
15	-	Et ₃ N (2.0 eq.)	80	H_2O	36
16	-	Et ₃ N (2.0 eq.)	80	DMSO	79

 $[\]overline{a}$ Reaction conditions: Step I: **1a** (0.5 mmol), tetramethylthiuram disulfide (**TMTD**, 0.3 mmol), solvent (2 mL), stirred in a sealed tube for 3 h. Step II: **2a** (1.0 mmol), catalyst (2 eq.), stirred in a sealed tube for 6 h. ^b Isolated yield.




Figure 2. X-ray crystallography of 3ai.

The above optimal reaction conditions were also applicable to the reactions between various substituted 2-aminobenzenethiols (1) and α,β -unsaturated esters (2). However, this reaction would give the C-S formation products (all oily) as major ones via Michael addition, and the C-N formation products were obtained in traces. Thus, under standard conditions, a variety of substituted 2-aminobenzenethiols (1) and TMTD could react with ethyl acrylate, *tert*-butyl acrylate and cyclohexyl acrylate, smoothly, giving the target products with a moderate yield (5aa–5ag, Table 3). To determine the detailed structure of the target product, the X-ray diffraction analysis of by-product 5ag' (CCDC: 2152790, Figure 3) was performed, showing the existence of the C-N bond formation, which could further indicate the C-S bond formation of the major product 5ag.





Figure 3. X-ray crystallography of by-product 5ag'.

Catalysts **2023**, 13, 658 5 of 13

Table 2. One-pot synthesis of benzoxazole-substituted ester compounds ^{a,b}.



^a Reaction conditions: Step I: 1 (0.5 mmol), tetramethylthiuram disulfide (TMTD, 0.3 mmol), DMF (2 mL), 80 $^{\circ}$ C, stirred in a sealed tube for 3 h. Step II: 2 (1.0 mmol), Et₃N (2.0 eq.), 80 $^{\circ}$ C, stirred in a sealed tube for 6 h. ^b Isolated yield.

Catalysts 2023, 13, 658 6 of 13

Table 3. One-pot synthesis of benzothiazole-substituted ester compounds ^{a,b}.

3. Conclusions

In summary, we developed an efficient and convenient one-pot method to selectively construct C-N and C-S bonds by a simple Michael addition. Using substituted 2-aminophenols/2-aminobenzenethiols, TMTD (tetramethylthiuram disulfide) and α,β -unsaturated esters as starting substrates, a variety of benzoxazole/benzothiazole substituted esters were obtained without problem, forming C-N and C-S bonds selectively. This strategy features high selectivity, high atomic economy, mild conditions, good functional tolerance. and good yields, showing its potential value for the preparation of some biologically and pharmaceutically active compounds.

4. Experimental Section

General Information. All starting materials were commercially purchased. Yields refer to isolated compounds estimated to be >95% pure as determined by ^1H NMR and capillary GC analysis. NMR spectra were recorded on a Bruker AM400 or AM 600 NMR instrument in CDCl $_3$ using TMS as an internal standard. Chemical shifts are given in ppm, and coupling constants (J) are given in Hz. All melting points were determined on a RY-1G melting point instrument without correction. High-resolution mass spectra (HRMS) were recorded on a Angilent 6545LC/Q-TOF mass instrument (ESI). TLC was performed using aluminum plates coated with SiO $_2$ (Merck 60, F-254) and visualized with UV light at 254 nm. Column chromatography was performed on silica gel (200–300 mesh) with PE (petroleum ether)-EA (ethyl acetate) as an eluent.

General procedure for the synthesis of desired products forming C-N bonds (**3aa–3av**). A mixture of substituted 2-aminophenols (**1**, 0.5 mmol) and tetramethylthiuram disulfide (**TMTD**, 0.3 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h until the substrates completely disappeared. Subsequently, the sealed tube was cooled to room temperature. **2** (ethyl acrylate, *tert*-butyl acrylate, or cyclohexyl acrylate, 1.0 mmol) and Et₃N (2.0 eq.) were added, and the mixture was stirred at 80 °C for 6 h. After the reaction was completed, it was quenched with saturated NH₄Cl, and the crude solution was separated after diluting with ethyl acetate and dried-over anhydrous Na₂SO₄. The solvent was removed in a vacuum to obtain the crude product, which was further separated and purified by column chromatography to give the desired products (**3aa–3av**).

General procedure for the synthesis of desired products forming C-S bonds (5aa-5ag).

 $^{^{\}overline{a}}$ Reaction conditions: Step I: 4 (0.5 mmol), tetramethylthiuram disulfide (TMTD, 0.3 mmol), DMF (2 mL), 80 °C, stirred in a sealed tube for 3 h. Step II: 2 (1.0 mmol), Et₃N (2.0 eq.), 80 °C, stirred in a sealed tube for 6 h. b Isolated yield.

Catalysts 2023, 13, 658 7 of 13

A mixture of substituted 2-aminobenzenethiols (4, 0.5 mmol) and tetramethylthiuram disulfide (TMTD, 0.3 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h until the substrates completely disappeared. Subsequently, the sealed tube was cooled to room temperature, 2 (ethyl acrylate, *tert*-butyl acrylate, or cyclohexyl acrylate, 1.0 mmol) and $\rm Et_3N$ (2.0 eq.) were added, and the mixture was stirred at 80 °C for 6 h. After the reaction was completed, it was quenched with saturated NH₄Cl, and the crude solution was separated after diluting with ethyl acetate and dried over anhydrous Na₂SO₄. The solvent was removed in a vacuum to obtain the crude product, which was further separated and purified by column chromatography to give the desired products (5aa–5ag).

ethyl 3-(2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3aa**): The target product **3aa** (106.8 mg, 85%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:10). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.27–7.14 (m, 4H), 4.37 (t, J = 6.8 Hz, 2H), 4.02 (q, J = 7.2 Hz, 2H), 2.88 (t, J = 6.8, 2H), 1.11 (t, J = 7.2 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ ppm: 179.0, 169.8, 146.1, 130.8, 123.9, 123.3, 109.3, 109.0, 60.1, 40.4, 30.3, 13.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₂H₁₄NO₃S⁺ 252.0689; Found 252.0682.

ethyl 3-(5-*bromo*-2-*thioxobenzo*[*d*]*oxazol*-3(2*H*)-*yl*)*propanoate* (**3ab**): The target product **3ab** (138.7 mg, 84%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 72–74 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.36 (d, J = 2.0, 1H), 7.29–7.25 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.32 (t, J = 6.8, 2H), 4.05 (q, J = 7.1 Hz, 2H), 1.14 (t, J = 7.0 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.3, 169.6, 145.1, 132.3, 126.1, 116.8, 112.2, 110.4, 60.2, 40.6, 30.2, 13.1. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₂H₁₃BrNO₃S⁺ 329.9794; Found 329.9797.

ethyl 3-(6-methyl-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3ac**): The target product **3ac** (108.8 mg, 82%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 58–60 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.10–7.01 (m, 3H), 4.35 (t, J = 6.8 Hz, 2H), 4.03 (q, J = 7.1 Hz, 2H), 2.87 (t, J = 8.6, 2H), 2.35 (s, 3H), 1.13 (t, J = 7.2 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 178.9, 169.9, 146.4, 138.7, 133.8, 128.6, 124.6, 109.8, 108.5, 60.1, 40.4, 30.3, 20.4, 13.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C_{13} H₁₆NO₃S⁺ 266.0845; Found 266.0842.

ethyl 3-(5-chloro-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3ad**): The target product **3ad** (111.4 mg, 78%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 58–60 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.23 (s, 1H), 7.18–7.08 (m, 2H), 4.32 (t, J = 6.6, 2H), 4.04 (q, J = 7.2, 2H), 2.88 (t, J = 6.6 Hz, 2H), 1.14 (t, J = 7.0 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.4, 169.6, 144.6, 132.0, 129.6, 123.2, 109.9, 109.5, 60.2, 40.7, 30.2, 13.1. HRMS (ESI) m/z [M + H] $^{+}$ Calcd for C₁₂H₁₃ClNO₃S $^{+}$ 286.0299; Found 286.0294.

ethyl 3-(5-(*tert-butyl*)-2-*mercaptobenzo*[*d*]*oxazol*-3(2*H*)-*yl*)*propanoate* (**3ae**): The target product **3ae** (135.3 mg, 88%) was synthesized as a yellow oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1H NMR (400 MHz, CDCl₃) δ ppm: 7.23–7.13 (m, 3H), 4.40 (t, J = 6.8 Hz, 2H), 4.03 (q, J = 7.1 Hz, 2H), 2.86 (t, J = 6.8, 2H), 1.28 (s, 9H), 1.10 (t, J = 7.2 Hz, 3H). 13 C{ 1H } NMR (100 MHz, CDCl₃) δ ppm: 179.3, 169.9, 147.8, 144.2, 130.5, 120.5, 108.5, 105.9, 60.0, 40.3, 34.1, 30.6, 30.5, 13.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₆H₂₂NO₃S⁺ 308.1315; Found 308.1316.

ethyl 3-(6-chloro-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3af**): The target product **3af** (75.7 mg, 53%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 90–92 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.27 (s, 1H), 7.20 (q, J = 9.9 Hz, 2H), 4.34 (t, J = 6.4 Hz, 2H), 4.03 (q, J = 7.1, 2H), 2.89 (t, J = 6.4 Hz, 2H), 1.13 (t, J = 7.1 Hz, 3H). 13 C[1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.1, 169.9, 146.2, 129.9, 129.1, 124.1, 109.9, 109.7, 60.2, 40.6, 30.2, 13.1. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₂H₁₃ClNO₃S⁺ 286.0299; Found 286.0297.

ethyl 3-(5-methyl-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3ag**): The target product **3ag** (92.9 mg, 70%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.20 (d,

Catalysts 2023, 13, 658 8 of 13

J = 8.9 Hz, 1H), 7.04 (d, J = 7.2 Hz, 2H), 4.42 (t, J = 6.9, 2H), 4.12 (q, J = 7.2, 2H), 2.94 (t, J = 6.9 Hz, 2H), 2.44 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.2, 169.8, 144.4, 134.2, 130.8, 124.0, 109.1, 108.9, 60.1, 40.3, 30.3, 20.5, 13.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₃H₁₆NO₃S⁺ 266.0845; Found 266.0851.

ethyl 3-(4-*methyl*-2-*thioxobenzo*[*d*]*oxazol*-3(2*H*)-*yl*)*propanoate* (**3ah**): The target product **3ah** (37.1 mg, 28%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 70–72 °C. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.19 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.8, 1H), 7.04 (d, J = 7.6, 1H), 4.68 (t, J = 7.8, 2H), 4.15 (q, J = 7.1 Hz, 2H), 2.93 (t, J = 7.8, 2H), 2.63 (s, 3H), 1.23 (t, J = 7.1, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ ppm: 179.4, 169.3, 146.4, 128.7, 127.0, 123.2, 119.7, 107.5, 60.1, 41.6, 31.2, 16.7, 13.1. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₃H₁₆NO₃S⁺ 266.0845; Found 266.0843

tert-butyl 3-(2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (3ai): The target product 3ai (120.1 mg, 86%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 88–90 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.28–7.15 (m, 4H), 4.35 (t, J = 6.9 Hz, 2H), 2.78 (t, J = 6.9 Hz, 2H), 1.31 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.1, 169.0, 146.1, 130.8, 123.9, 123.3, 109.3, 109.1, 80.6, 40.5, 31.5, 27.0. HRMS (ESI) m/z [M + H] $^{+}$ Calcd for C₁₄H₁₈NO₃S $^{+}$ 280.1002; Found 280.1006.

tert-butyl 3-(4-methyl-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (3aj): The target product 3aj (42.5 mg, 29%) was synthesized as a yellow oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.20 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 4.65 (t, J = 7.9 Hz, 2H), 2.84 (t, J = 8.0 Hz, 2H), 2.63 (s, 3H), 1.43 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.3, 168.5, 146.4, 128.7, 127.0, 123.2, 119.8, 107.5, 80.7, 41.8, 32.4, 27.3, 16.7. HRMS (ESI) m/z [M + H] $^+$ Calcd for C₁₅H₂₀NO₃S $^+$ 294.1158; Found 294.1156.

tert-butyl 3-(6-methyl-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3ak**): The target product **3ak** (130.6 mg, 89%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 66–68 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.13 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 8.4 Hz, 1H), 4.37 (t, J = 6.9 Hz, 2H), 2.82 (t, J = 6.9 Hz, 2H), 2.41 (s, 3H), 1.38 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 178.9, 169.1, 146.4, 133.8, 128.6, 124.5, 109.7, 108.6, 80.6, 40.5, 31.5, 27.0, 20.4. HRMS (ESI) m/z [M + H]+ Calcd for C₁₅H₂₀NO₃S+ 294.1158; Found 294.1163.

tert-butyl 3-(5-(tert-butyl)-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3al**): The target product **3al** (122.4 mg, 73%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.29–7.26 (m, 2H), 7.24 (d, J = 9.0 Hz, 1H), 4.44 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 6.9 Hz, 2H), 1.38 (s, 9H), 1.36 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 180.4, 170.3, 148.8, 145.2, 131.6, 121.5, 109.6, 107.1, 81.6, 41.4, 35.1, 32.6, 31.6, 28.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₈H₂₆NO₃S⁺ 336.1628; Found 336.1626.

tert-butyl 3-(5-bromo-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3am**): The target product **3am** (150.5 mg, 84%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 136–138 °C. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.43 (d, J = 1.8 Hz, 1H), 7.35 (dd, J = 8.6, 1.8 Hz, 1H), 7.19 (d, J = 8.6 Hz, 1H), 4.36 (t, J = 6.8 Hz, 2H), 2.82 (t, J = 6.8 Hz, 2H), 1.40 (s, 9H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ ppm: 179.3, 168.9, 145.1, 132.2, 126.1, 116.8, 112.2, 110.4, 80.9, 40.8, 31.5, 27.0. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₄H₁₇BrNO₃S⁺ 358.0107; Found 358.0112.

tert-butyl 3-(6-chloro-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3an**): The target product **3an** (109.8 mg, 70%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 88–90 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.27 (d, J = 1.7 Hz, 1H), 7.21 (dd, J = 8.5, 1.7 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 4.31 (t, J = 6.6 Hz, 2H), 2.78 (t, J = 6.6 Hz, 2H), 1.32 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.1, 169.1, 146.2, 129.8, 129.0, 124.1, 109.9, 109.7, 80.7, 40.7, 31.4, 27.0. HRMS (ESI) m/z [M + H] $^+$ Calcd for C₁₄H₁₇ClNO₃S $^+$ 314.0612; Found 314.0606.

cyclohexyl 3-(2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3ao**): The target product **3ao** (135.9 mg, 89%) was synthesized as a colorless oil, and purified by column chromatography

Catalysts 2023, 13, 658 9 of 13

(ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.26–7.13 (m, 4H), 4.68–4.60 (m, 1H), 4.37 (t, J = 6.8 Hz, 2H), 4.79–4.71 (t, J = 6.8 Hz, 2H), 3.47 (t, J = 6.8 Hz, 2H), 2.86 (t, J = 6.7 Hz, 2H), 1.71–1.64 (m, 2H), 1.61–1.54 (m, 2H), 1.46–1.14 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.1, 169.4, 146.2, 130.9, 123.9, 123.3, 109.3, 109.1, 72.7, 40.5, 30.7, 30.4, 24.2, 22.6. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₆H₂₀NO₃S⁺ 306.1158; Found 306.1155.

cyclohexyl 3-((6-methylbenzo[d]oxazol-2-yl)thio)propanoate (**3ap**): The target product **3ap** (110.2 mg, 69%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.45 (d, J = 8.1 Hz, 1H), 7.23 (s, 1H), 7.08 (dd, J = 8.1, 0.8 Hz, 1H), 4.85–4.78 (m, 1H), 3.52 (t, J = 7.1 Hz, 2H), 2.90 (t, J = 6.9 Hz, 2H), 2.45 (s, 3H), 1.90–1.81 (m, 2H), 1.76–1.67 (m, 2H), 1.54–1.23 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 169.8, 162.6, 151.2, 138.7, 133.3, 124.3, 116.7, 109.2, 72.4, 33.7, 30.6, 26.2, 24.3, 22.7, 20.6. HRMS (ESI) m/z [M + H] $^+$ Calcd for C₁₇H₂₂NO₃S $^+$ 320.1315; Found 320.1316.

cyclohexyl 3-(5-(*tert-butyl*)-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3aq**): The target product **3aq** (126.5 mg, 70%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.20 (dd, J = 8.5, 1.7 Hz, 1H), 7.18–7.14 (m, 2H), 4.68–4.59 (m, 1H), 4.39 (t, J = 6.8 Hz, 2H), 2.83 (t, J = 6.8 Hz, 2H), 1.67–1.53 (m, 4H), 1.46–1.06 (m, 16H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.2, 169.4, 147.8, 144.2, 130.5, 120.5, 108.5, 106.0, 72.5, 40.4, 34.1, 30.8, 30.6, 30.4, 24.2, 22.6. HRMS (ESI) m/z [M + H]⁺ Calcd for C₂₀H₂₈NO₃S⁺ 362.1784; Found 362.1777.

cyclohexyl 3-(4-*methyl*-2-thioxobenzo[*d*]oxazol-3(2*H*)-*yl*)propanoate (**3ar**): The target product **3ar** (57.5 mg, 36%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 78–80 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.20 (d, J = 7.7 Hz, 1H), 7.13 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 4.82–4.75 (m, 1H), 4.68 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 2.63 (s, 3H), 1.85–1.78 (m, 2H), 1.73–1.65 (m, 2H), 1.56–1.26 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.3, 168.7, 146.4, 128.7, 127.0, 123.2, 119.8, 107.5, 72.6, 41.7, 31.6, 30.5, 24.3, 22.6, 16.7. HRMS (ESI) m/z [M + H]⁺ Calcd for $C_{17}H_{22}NO_3S^+$ 320.1315; Found 320.1313.

cyclohexyl 3-(5-*bromo*-2-*thioxobenzo*[*d*]*oxazol*-3(2*H*)-*yl*)*propanoate* (**3as**): The target product **3as** (153.7 mg, 80%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 96–98 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.42 (d, J = 1.8 Hz, 1H), 7.34 (dd, J = 8.6, 1.8 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 4.77–4.68 (m, 1H), 4.37 (t, J = 6.6 Hz, 2H), 2.91 (t, J = 6.6 Hz, 2H), 1.82–1.73 (m, 2H), 1.69–1.62 (m, 2H), 1.55–1.21 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.3, 169.2, 145.1, 132.3, 126.1, 116.8, 112.3, 110.4, 72.9, 40.7, 30.6, 30.5, 24.2, 22.7. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₆H₁₉BrNO₃S⁺ 384.0264; Found 384.0266.

cyclohexyl 3-(6-chloro-2-thioxobenzo[d]oxazol-3(2H)-yl)propanoate (**3at**): The target product **3at** (149.5 mg, 88%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 86–88 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.27 (d, J = 1.6 Hz, 1H), 7.22 (dd, J = 8.5, 1.7 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 4.68–4.60 (m, 1H), 4.33 (t, J = 6.5 Hz, 2H), 2.87 (t, J = 6.5 Hz, 2H), 1.72–1.65 (m, 2H), 1.62–1.55 (m, 2H), 1.46–1.14 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.1, 169.4, 146.2, 129.9, 129.0, 124.1, 109.9, 109.7, 72.8, 40.7, 30.5, 30.4, 24.2, 22.6. HRMS (ESI) m/z [M + H]+ Calcd for C₁₆H₁₉ClNO₃S+ 340.0769; Found 340.0776.

cyclohexyl 3-(5-*chloro*-2-*thioxobenzo[d]oxazol*-3(2*H*)-*yl)propanoate* (**3au**): The target product **3au** (95.2 mg, 56%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 110–112 °C. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.30 (d, J = 1.6 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 7.20 (dd, J = 8.6, 1.8 Hz, 1H), 4.77–4.69 (m, 1H), 4.38 (t, J = 6.6 Hz, 2H), 2.93 (t, J = 6.6 Hz, 2H), 1.82–1.73 (m, 2H), 1.72–1.63 (m, 2H), 1.52–1.20 (m, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ ppm: 179.5, 169.2, 144.6, 132.0, 129.8, 123.2, 109.9, 109.5, 72.9, 40.7, 30.6, 30.5, 24.2, 22.7. HRMS (ESI) m/z [M + H]+ Calcd for C₁₆H₁₉ClNO₃S+ 340.0769; Found 340.0766.

Catalysts 2023, 13, 658 10 of 13

cyclohexyl 3-(5-*methyl*-2-thioxobenzo[*d*]oxazol-3(2*H*)-*yl*)propanoate (**3av**): The target product **3av** (138.9 mg, 87%) was synthesized as a white solid, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). mp: 98–100 °C. 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.19 (d, J = 8.2 Hz, 1H), 7.06–7.00 (m, 2H), 4.76–4.69 (m, 1H), 4.41 (t, J = 6.9 Hz, 2H), 2.91 (t, J = 6.9 Hz, 2H), 2.43 (s, 3H), 1.80–1.72 (m, 2H), 1.69–1.63 (m, 2H), 1.54–1.19 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 179.2, 169.3, 144.4, 134.1, 130.8, 124.0, 109.2, 108.8, 72.7, 40.4, 30.7, 30.5, 24.2, 22.6, 20.5. HRMS (ESI) m/z [M + H]⁺ Calcd for C_{17} H₂₂NO₃S⁺ 320.1315; Found 320.1321.

ethyl 3-(benzo[d]thiazol-2-ylthio)propanoate (**5aa**): The target product **5aa** (88.2 mg, 66%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:10). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.48 (dd, J = 8.0, 4.0 Hz, 1H), 7.44–7.39 (m, 1H), 7.34–7.27 (m, 2H), 5.00 (t, J = 4.0, 2H), 4.12 (q, J = 8.0 Hz, 2H), 2,87 (t, J = 8.0 Hz, 2H), 1.21 (t, J = 8.0 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 186.6, 169.8, 156.5, 134.2, 127.9, 113.4, 112.0, 104.7, 60.1, 54.9, 41.0, 30.3, 13.1. HRMS (ESI) m/z [M + H]+ Calcd for C₁₂H₁₃NO₂S₂+ 268.0460; Found 268.0463.

tert-butyl 3-(benzo[d]thiazol-2-ylthio)propanoate (**5ab**): The target product **5ab** (104.9 mg, 71%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.30 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 7.6, 1H), 7.18–7.09 (m, 2H), 4.49 (t, J = 7.6, 2H), 2.60 (t, J = 7.6 Hz, 2H), 1.25 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 188.1, 169.0, 140.2, 126.7, 126.0, 123.8, 120.4, 111.5, 80.5, 41.0, 31.4, 27.0. HRMS (ESI) m/z [M + H]+ Calcd for C₁₄H₁₈NO₂S₂+ 296.0773; Found 296.0771.

cyclohexyl 3-(*benzo*[*d*]*thiazol-2-ylthio*)*propanoate* (**5ac**): The target product **5ac** (99.7 mg, 62%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) 5 ppm: 7.40 (d, 5 J = 7.8 Hz, 1H), 7.34 (t, 5 J = 7.2 Hz, 1H), 7.28–7.18 (m, 2H), 4.71–4.64 (m, 1H), 4.61 (t, 5 J = 7.4 Hz, 2H), 2.78 (t, 5 J = 7.4 Hz, 2H), 1.73–1.57 (m, 4H), 1.46–1.1.13 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) 5 ppm: 188.1, 169.2, 140.2, 126.7, 126.0, 123.8, 120.4, 111.5, 72.5, 41.0, 30.6, 30.4, 24.3, 22.6. HRMS (ESI) 12 M/z [M + H]+ Calcd for C 12 M-2 12 M-2 12 M-2 322.0930; Found 322.0935.

ethyl 3-((5-chlorobenzo[d]thiazol-2-yl)thio)propanoate (**5ad**): The target product **5ad** (66.4 mg, 44%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:15). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.31 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.21 (dd, J = 8.4, 1.8 Hz, 1H), 4.58 (t, J = 7.4, 2H), 4.09 (q, J = 7.2 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 188.9, 169.6, 141.1, 132.4, 124.9, 124.0, 121.0, 111.7, 60.2, 401.1, 30.2, 13.1. HRMS (ESI) m/z [M + H] $^{+}$ Calcd for C₁₂H₁₃ClNO₂S₂ $^{+}$ 302.0071; Found 302.0068.

tert-butyl 3-((5-chlorobenzo[d]thiazol-2-yl)thio)propanoate (5ae): The target product 5ae (100.6 mg, 61%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.35 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 1.6 Hz, 1H), 7.26–7.23 (m, 1H), 4.59 (t, J = 7.4 Hz, 2H), 2.74 (t, J = 7.4 Hz, 2H), 1.41 (s, 9H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 188.1, 169.8, 140.2, 126.7, 126.0, 123.8, 120.4, 111.4, 60.1, 40.9, 30.3, 13.1. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₄H₁₇ClNO₂S₂⁺ 330.0384; Found 330.0386.

cyclohexyl 3-((5-chlorobenzo[d]thiazol-2-yl)thio)propanoate (**5af**): The target product **5af** (99.7 mg, 62%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.39 (d, J = 8.4 Hz, 1H), 7.35 (s, 1H), 7.22–7.17 (m, 1H), 4.74–4.66 (m, 1H), 4.64 (t, J = 7.2 Hz, 2H), 2.86 (t, J = 7.2 Hz, 2H), 1.87–1.77 (m, 2H), 1.74–1.65 (m, 2H), 1.52–1.18 (m, 6H). 13 C{ 1 H} NMR (100 MHz, CDCl₃) δ ppm: 188.8, 169.1, 141.1, 132.4, 124.9, 124.0, 121.0, 111.7, 72.7, 41.2, 30.6, 30.5, 24.3, 22.7. HRMS (ESI) m/z [M + H] $^+$ Calcd for C₁₆H₁₉ClNO₂S₂ $^+$ 356.0540; Found 356.0536.

tert-butyl 3-((6-methoxybenzo[d]thiazol-2-yl)thio)propanoate (**5ag**): The target product **5ag** (113.9 mg, 70%) was synthesized as a colorless oil, and purified by column chromatography (ethyl acetate/petroleum ether = 1:7). 1 H NMR (400 MHz, CDCl₃) δ ppm: 7.16 (d, J = 8.8 Hz,

Catalysts 2023, 13, 658 11 of 13

1H), 6.93–6.87 (m, 2H), 4.53 (t, J = 7.4 Hz, 2H), 3.75 (s, 3H), 2.69 (t, J = 7.4 Hz, 2H), 1.34 (s, 9H). 13 C NMR (100 MHz, CDCl₃) δ ppm: 186.1, 168.5, 156.0, 133.8, 127.4, 112.9, 111.6, 104.1, 80.0, 54.4, 40.6, 30.9, 26.5. HRMS (ESI) m/z [M + H]⁺ Calcd for C₁₅H₂₀NO₃S₂⁺ 326.0879; Found 326.0871.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/catal13040658/s1, Characterization data for all products, X-ray diffraction analysis of compound **3ai** and **5ag**′, ¹H-NMR and ¹³C-NMR spectra of all products. Deposition Numbers 2152790 (for **5ag**′), 2152821 (for **3ai**) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe "http://www.ccdc.cam.ac.uk/structures".

Author Contributions: Methodology, Z.-Y.G.; writing—review and editing, Z.-Y.G. and C.-L.Y.; methodology, D.W.; review and editing, L.H.; supervision, Z.-B.D.; project administration, Z.-B.D. All authors have read and agreed to the published version of the manuscript.

Funding: The financial support from the Open Research Fund of School of Chemistry and Chemical Engineering, Henan Normal University (2020ZD02), the Natural Science Foundation of Henan Province (232300421126) is greatly appreciated.

Data Availability Statement: Data supporting reported results can be found in Supplementary Materails.

Acknowledgments: Z.-Y.G. is thankful for the support of Postgraduate Innovation Foundation from Wuhan Institute of Technology.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Huang, W.; Yang, G.F. Microwave-Assisted, One-Pot Syntheses and Fungicidal Activity of Polyfluorinated 2-Benzylthiobenzothiazoles. *Bioorg. Med. Chem.* **2006**, *14*, 8280–8285. [CrossRef] [PubMed]
- 2. Singh, S.P.; Segal, S. Study of Fungicidal Activities of Some Benzothiazoles. *Indian J. Chem.* 1988, 27B, 941–943.
- 3. Akhtar, T.; Hameed, S.; Al-Masoudi, N.A.; Loddo, R.; Colla, P. In Vitro Antitumor and Antiviral Activities of New Benzothiazole and 1, 3, 4-Oxadiazole-2-Thione Derivatives. *Acta Pharm.* **2008**, *58*, 135–149. [CrossRef] [PubMed]
- 4. Huang, S.T.; Hsei, I.J.; Chen, C. Synthesis and Anticancer Evaluation of Bis (Benzimidazoles), Bis (Benzoxazoles), and Benzothiazoles. *Bioorg. Med. Chem.* **2006**, *14*, 6106–6119.
- 5. Palmer, P.J.; Trigg, R.B.; Warrington, J.V. Benzothiazolines as Antituberculous Agents. J. Med. Chem. 1971, 14, 248–251. [CrossRef]
- 6. Rao, A.J.; Rao, P.V.; Rao, V.K.; Mohan, C.; Raju, C.N.; Reddy, C.S. Microwave Assisted One-Pot Synthesis of Novel a-Aminophosphonates and Their Biological Activity. *Bull. Korean Chem. Soc.* **2010**, *31*, 1863–1868. [CrossRef]
- 7. Singh, M.; Singh, S.K.; Gangwar, M.; Nath, G.; Singh, S.K. Design, Synthesis and Mode of Action of Some Benzothiazole Derivatives Bearing an Amide Moiety as Antibacterial Agents. *RSC Adv.* **2014**, *4*, 19013–19023. [CrossRef]
- 8. Suresh, C.H.; Rao, J.V.; Jayaveera, K.N.; Subudhi, S.K. Synthesis and Anthelminitc Activity of 3 (2-Hydrazino Benzothiazoles)-Substituted Indole-2-One. *Int. Res. J. Pharm.* **2011**, 2, 257–261.
- 9. Reddy, P.; Lin, Y.; Chang, H. Synthesis of Novel Benzothiazole Compounds with an Extended Conjugated System. *Arkivoc* **2007**, 16, 113–122. [CrossRef]
- 10. Heo, Y.; Song, Y.S.; Kim, B.T.; Heo, J.N. A Highly Regioselective Synthesis of 2-Aryl-6-Chlorobenzothiazoles Employing Microwave-Promoted Suzuki-Miyaura Coupling Reaction. *Tetrahedron Lett.* **2006**, *47*, 3091–3094. [CrossRef]
- 11. Azam, M.A.; Suresh, B. Biological Activities of 2-Mercaptobenzothiazole Derivatives: A Review. *Sci. Pharm.* **2012**, *80*, 789–824. [CrossRef]
- 12. Dumas, J.; Brittelli, D.; Chen, J.; Dixon, B.; Hatoum-Mokdad, H.; Konig, G.; Sibley, R.; Witowsky, J.; Wong, S. Synthesis and Structure Activity Relationships of Novel Small Molecule Cathepsin D Inhibitors. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2531–2536. [CrossRef]
- 13. Pejin, B.; Iodice, C.; Tommonaro, G.; Rosa, S.D. Synthesis and Biological Activities of Thio-Avarol Derivatives. *J. Nat. Prod.* **2008**, 71, 1850–1853. [CrossRef]
- 14. Han, Y.; Dong, W.; Guo, Q.Q.; Li, X.F.; Huang, L.J. The Importance of Indole and Azaindole Scaffold in the Development of Antitumor Agents. *Eur. J. Med. Chem.* **2020**, 203, 112506. [CrossRef] [PubMed]
- 15. Zhang, L.; Fan, J.; Vu, K.; Hong, K.; Le Brazidec, J.Y.; Shi, J.; Biamonte, M.; Busch, D.J.; Lough, R.E.; Grecko, R.; et al. 7'-Substituted Benzothiazolothio-and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors. *J. Med. Chem.* **2006**, 49, 5352–5362. [CrossRef] [PubMed]

Catalysts 2023, 13, 658 12 of 13

16. Zhi, X.Y.; Jiang, L.Y.; Li, T.; Song, L.L.; Wu, L.J.; Cao, H.; Yang, C. Natural Product-Based Semisynthesis and Biological Evaluation of Thiol/Amino-Michael Adduct of Xanthatin Derived from Xanthium Strumarium as Potential Pesticidal Agents. *Bioorg. Chem.* **2020**, *97*, 103696. [CrossRef]

- 17. Gorla, S.K.; Kavitha, M.; Zhang, M.; Chin, J.E.; Liu, X.; Striepen, B.; Makowska-Grzyska, M.; Kim, Y.; Joachimiak, A.; Hedstrom, L.; et al. Optimization of Benzoxazole-Based Inhibitors of Cryptosporidium Parvum Inosine 5'-Monophosphate Dehydrogenase. *J. Med. Chem.* 2013, 56, 4028–4043. [CrossRef]
- 18. Naya, A.; Kobayashi, K.; Ishikawa, M.; Ohwaki, K.; Saeki, T.; Noguchi, K.; Ohtake, N. Discovery of a Novel CCR3 Selective Antagonist. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1219–1223. [CrossRef]
- 19. Choudhary, A.N.; Kumar, A.; Juyal, V. Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors. *Mini-Rev. Med. Chem.* **2010**, *10*, 705–714. [CrossRef] [PubMed]
- 20. Chekal, B.P.; Guinness, S.M.; Lillie, B.M.; McLaughlin, R.W.; Palmer, C.W.; Post, R.J.; Sieser, J.E.; Singer, R.A.; Sluggett, G.W.; Vaidyanathan, R.; et al. Development of an Efficient Pd-Catalyzed Coupling Process for Axitinib. *Org. Process Res. Dev.* **2013**, *18*, 266–274. [CrossRef]
- 21. Klimešová, V.; Kočí, J.; Pour, M.; Stachel, J.; Waisser, K.; Kaustová, J. Synthesis and Preliminary Evaluation of Benzimidazole Derivatives as Antimicrobial Agents. *Eur. J. Med. Chem.* **2002**, *37*, 409–418. [CrossRef] [PubMed]
- 22. Larsson, P.F.; Correa, A.; Carril, M.; Norrby, P.O.; Bolm, C. Copper-Catalyzed Cross-Couplings with Part-per-Million Catalyst Loadings. *Angew. Chem. Int. Ed.* **2009**, *48*, 5691. [CrossRef] [PubMed]
- 23. Ueda, S.; Buchwald, S.L. Catalyst-Controlled Chemoselective Arylation of 2-Aminobenzimidazoles. *Angew. Chem. Int. Ed.* **2012**, 51, 10364–10367. [CrossRef]
- 24. Li, X.; Yuan, T.; Yang, Y.; Chen, J. Novel Copper/PEG-400 Catalyst Systems for Chemoselective *S* and *N*-arylation of 2-Mercaptobenzothiazole. *Tetrahedron* **2014**, 70, 9652–9660. [CrossRef]
- Duari, S.; Biswas, S.; Roy, A.; Maity, S.; Mishra, A.K.; Souza, A.R.; Elsharif, A.M.; Morgon, N.H.; Biswas, S. Regioselective N-Functionalization of Tautomerizable Heterocycles through Methyl Trifluoromethanesulfonate-Catalyzed Substitution of Alcohols and Alkyl Group Migrations. *Adv. Synth. Catal.* 2022, 364, 865–872. [CrossRef]
- 26. Herrera Cano, N.; Ballari, M.S.; Lopez, A.G.; Santiago, A.N. New Synthesis and Biological Evaluation of Benzothiazole Derivates as Antifungal Agents. *J. Agric. Food. Chem.* **2015**, *63*, 3681–3686. [CrossRef] [PubMed]
- 27. Ghaderi-Shekhi Abadi, P.; Rafiee, E.; Joshaghani, M. Pd-PVP-Fe (Palladium-Poly(N-vinylpyrrolidone)-iron) Catalyzed S-arylation of Thiols with Aryl Halides in Aqueous Media. *Inorg. Chim. Acta.* **2016**, *451*, 162–170. [CrossRef]
- 28. Sikari, R.; Sinha, S.; Das, S.; Saha, A.; Chakraborty, G.; Mondal, R.; Paul, N.D. Achieving Nickel Catalyzed C-S Cross-Coupling under Mild Conditions Using Metal-Ligand Cooperativity. *J. Org. Chem.* **2019**, *84*, 4072–4085. [CrossRef]
- 29. Feng, Y.-S.; Li, Y.-Y.; Tang, L.; Wu, W.; Xu, H.-J. Efficient Ligand-Free Copper-Catalyzed C-S Cross-Coupling of Thiols with Aryl Iodides Using KF/Al₂O₃ as Base. *Tetrahedron Lett.* **2010**, *51*, 2489–2492. [CrossRef]
- 30. Wu, W.-Y.; Wang, J.-C.; Tsai, F.-Y. A Reusable FeCl₃-6H₂O/Cationic 2,2'-Bipyridyl Catalytic System for the Coupling of Aryl Iodides with Thiols in Water under Aerobic Conditionst. *Green Chem.* **2009**, *11*, 326–329. [CrossRef]
- 31. Correa, A.; Carril, M.; Bolm, C. Iron-Catalyzed S-Arylation of Thiols with Aryl Iodides. *Angew. Chem. Int. Ed.* **2008**, 47, 2880–2883. [CrossRef] [PubMed]
- 32. Sokolova, A.S.; Yarovaya, O.I.; Shtro, A.A.; Borisova, M.S.; Morozova, E.A.; Tolstikova, T.G.; Zarubaev, V.V.; Salakhutdinov, N.F. Synthesis and Biological Activity of Heterocyclic Borneol Derivatives. *Chem. Heterocycl. Compd.* **2017**, *53*, 371–377. [CrossRef]
- 33. Shi, L.; Liu, X.; Zhang, H.; Jiang, Y.; Ma, D. Synthesis of 2-Thio-Substituted Benzothiazoles via a Domino Condensation/S-Arylation/Heterocyclization Process. *J. Org. Chem.* **2011**, *76*, 4200–4204. [CrossRef] [PubMed]
- 34. Kibriya, G.; Mondal, S.; Hajra, A. Visible-Light-Mediated Synthesis of Unsymmetrical Diaryl Sulfides via Oxidative Coupling of Arylhydrazine with Thiol. *Org. Lett.* **2018**, *20*, 7740–7743. [CrossRef]
- 35. Ren, X.; Tang, S.; Li, L.; Li, J.; Liang, H.; Li, G.; Yang, G.; Li, H.; Yuan, B. Surfactant-Type Catalyst for Aerobic Oxidative Coupling of Hydrazine with Thiol in Water. *J. Org. Chem.* **2019**, *84*, 8683–8690. [CrossRef]
- 36. Xu, H.J.; Zhao, Y.Q.; Feng, T.; Feng, Y.S. Chan-Lam-Type S-Arylation of Thiols with Boronic Acids at Room Temperature. J. Org. Chem. 2012, 77, 2878–2884. [CrossRef]
- 37. Liu, X.; Dong, Z.B. Chemoselective Chan-Lam Coupling Reactions between Benzimidazoline-2-thiones and Arylboronic Acids. *J. Org. Chem.* **2019**, *84*, 11524–11532. [CrossRef]
- 38. Bhowmik, A.; Yadav, M.; Fernandes, R.A. Room Temperature Nickel-Catalyzed Cross-Coupling of Aryl-Boronic Acids with Thiophenols: Synthesis of Diarylsulfides. *Org. Biomol. Chem.* **2020**, *18*, 2447–2458. [CrossRef]
- 39. Quan, Z.J.; Ren, R.G.; Da, Y.X.; Zhang, Z.; Wang, X.C. Alkylation of SH-Heterocycles with Diethyl Phosphite Using Tetra-chloroethylene as an Efficient Solvent. *Heteroat. Chem.* **2011**, 22, 653–658. [CrossRef]
- 40. Anan'Eva, K.V.; Rozhkova, N.K. Benzazolin-2-Thiones in the Michael Reaction. 2. Reaction of Benzothiazolin-and Benzoxazolin-2-Thiones with Acrylanitrile, Acrylamide, and Methyl Acrylate in the Presence of Basic Catalysts. *Chem. Heterocycl. Compd.* **1986**, 22, 564–567. [CrossRef]
- 41. Dong, Z.B.; Liu, X.; Bolm, C. Copper-Catalyzed C(sp²)-S Coupling Reactions for the Synthesis of Aryl Dithiocarbamates with Thiuram Disulfide Reagents. *Org. Lett.* **2017**, *19*, 5916–5919. [CrossRef] [PubMed]
- 42. Dong, Z.B.; Balkenhohl, M.; Tan, E.; Knochel, P. Synthesis of Functionalized Diaryl Sulfides by Cobalt-Catalyzed Coupling between Arylzinc Pivalates and Diaryl Disulfides. *Org. Lett.* **2018**, *20*, 7581–7584. [CrossRef] [PubMed]

Catalysts 2023, 13, 658 13 of 13

43. Gao, M.Y.; Li, J.H.; Zhang, S.B.; Chen, L.J.; Li, Y.S.; Dong, Z.B. A Mild Synthesis of 2-Substituted Benzothiazoles via Nickel-Catalyzed Intramolecular Oxidative C-H Functionalization. *J. Org. Chem.* **2020**, *85*, 493–500. [CrossRef] [PubMed]

- 44. Wang, D.; Peng, H.Y.; Yang, M.M.; Hao, E.J.; Li, Y.S.; Dong, Z.B. Cs₂CO₃-Promoted Hydrothiolation of Alkynes with Aryl Thioureas: Stereoselective Synthesis of (*Z*)-Vinyl Sulfides. *J. Org. Chem.* **2021**, *86*, 8457–8464. [CrossRef] [PubMed]
- 45. Liu, X.; Liu, M.; Xu, W.; Zeng, M.T.; Zhu, H.; Chang, C.Z.; Dong, Z.B. An Environmentally Benign and Efficient Synthesis of Substituted Benzothiazole-2-thiols, Benzoxazole-2-thiols, and Benzimidazoline-2-thiones in Water. *Green Chem.* 2017, 19, 5591–5598. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.